Publication

Varenicline for Smoking Cessation in Patients with Coronary Heart Disease

Ockene, Ira S.
Salmoirago-Blotcher, Elena
Citations
Altmetric:
Student Authors
Elena Salmoirago Blotcher
Faculty Advisor
Academic Program
Clinical and Population Health Research
Document Type
Editorial
Publication Date
2010-01-19
Subject Area
Embargo Expiration Date
Abstract

Despite the decline in cigarette smoking over the past 40 years, self-reported data from the National Health Interview Survey show that 19.8% (43.4 million) of US adults were still smokers in 2007.1 Attempts to quit during the previous year in the general population decreased from 47% in 1993 to 38.8% in 2007, and only 4% to 7% of smokers trying to quit each year will eventually succeed. Cardiovascular diseases are the leading cause of death in Western countries, and cigarette smoking has a clear cause-and-effect relationship with atherosclerotic disease with the risk of myocardial infarction (MI) increasing with the number of cigarettes smoked.

Similarly strong evidence indicates that smoking cessation alone can result in a 36% reduction in the crude relative risk of mortality in smokers who quit versus those who do not.5 The risk decreases rapidly: after only 1 year of cessation, quitters have a lower relative risk (RR=0.63) of death from coronary heart disease (CHD) than do nonquitters, which decreases even further (RR=0.38) after 3 years of cessation. Consequently, efforts to find effective treatments to enhance smoking cessation are of great importance.

Source
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
PubMed ID
20048200
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Citation: Ockene I, Salmoirago-Blotcher E. Varenicline for smoking cessation in patients with coronary heart disease. Circulation. Jan 19 2010;121(2):188-190.
Distribution License